Roche and Icagen have agreed on a licensing and collaboration deal around ion channel modulators for neurological disorders. The duo did not disclose Roche’s upfront payment or research funding, but Icagen stands to receive up to $274 million in development and commercial milestones. The pair will work on small molecules using Icagen’s platform for ion
A study, conducted by Boston-based Reputation Institute, collated more than 16,500 reputation ratings collected throughout the U.S., Europe and Brazil during first two months of this year has ranked AbbVie No. 1. Who is then closely followed by Novo Nordisk and Takeda, who edged out rivals from a group of 17 companies to earn spots
Roche is doubling down on its anti-amyloid beta antibody crenezumab by starting a second phase 3 trial in patients with prodromal to mild Alzheimer’s disease after getting a look at binding, dose escalation and drug-disease progression model data late last year. A phase 2 trial of crenezumab, which Roche’s Genentech licensed from AC Immune in
